KROS – keros therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers [Yahoo! Finance]
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine [Seeking Alpha]
Form 8-K Keros Therapeutics, Inc. For: Mar 31
Form 8-K Keros Therapeutics, Inc. For: Mar 05
Form 8-K Keros Therapeutics, Inc. For: Feb 28
Form S-8 Keros Therapeutics, Inc.
Form 10-K Keros Therapeutics, Inc. For: Dec 31
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.